Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Dermira, Inc.    DERM

DERMIRA, INC.

(DERM)
  Report
Delayed Quote. Delayed Nasdaq - 02/14 04:00:00 pm
18.74 USD   --.--%
02/11DERMIRA : Amended tender offer statement by Third Party
PU
02/10AMENDED STATEMENT OF OWNERSHIP : Solicitation
PU
02/10DERMIRA : Statement of Ownership
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Dermira : Eli Lilly targets quarterly deals of $1 billion-$5 billion in 2020 - CFO

share with twitter share with LinkedIn share with facebook
share via e-mail
01/16/2020 | 06:23pm EST
FILE PHOTO: Eli Lilly and Company Senior Vice President and CFO Josh Smiley speaks during an interview in San Francisco

Eli Lilly and Co aims to announce roughly one $1 billion (765 million pounds) to $5 billion (3.8 billion pounds) deal every quarter in 2020, its chief financial officer told Reuters, as the U.S. drugmaker looks to build up its pipeline of future products.

It will focus largely on earlier stage opportunities across key therapeutic areas including oncology, pain, immunology, and neurology, CFO John Smiley told Reuters in an interview at the JP Morgan Healthcare conference in San Francisco earlier this week.

Eli Lilly has been on a deal-making spree in recent years in a bid to increase products and sales in core franchises as older blockbuster medicines, such as diabetes treatment Humalog, face generic competition and pressure to lower prices.

Last week, it announced a $1.1 billion deal to buy dermatology products maker Dermira Inc. With the purchase, Lilly will acquire Dermira's experimental treatment for atopic dermatitis, a serious form of eczema, which is in late-stage testing, as well as an approved medicated cloth to treat excessive armpit sweating.

"We are looking at Dermira-like opportunities targeting assets in the $1 billion to $5 billion range," Smiley said. "We'd like to be doing something in the range of one per quarter or so."

In 2018 and 2019, it announced several deals for cancer companies, including an $8 billion acquisition of Loxo Oncology. U.S. regulators in 2018 approved Vitrakvi, Loxo's first commercial medicine, which treats a wide variety of cancers triggered by a rare genetic mutation.

In a presentation to investors this week, Lilly Chief Executive David Ricks said most of its deals will be in the cancer space, but that other therapeutic areas remain of strong interest as well.

While the company is still looking at late-stage assets, Smiley said the most opportunity for shareholders is in drugs in earlier stages of development.

Deals could include licensing agreements, outright acquisitions, or other structures, he added.

In its most recent earnings call, Lilly forecast a higher-than-expected profit for 2020, citing growing demand for its newer medicines including diabetes drug Trulicity and Taltz for psoriasis and other related autoimmune diseases.

However, sales of Trulicity and other newer medicines have been crimped by high rebates and discounts drugmakers pay to middlemen, such as pharmacy benefit managers, in order to make sure patients have access to their products.

(Reporting by Carl O'Donnell; Additional reporting by Rebecca Spalding and Robin Respaut; Editing by Bill Berkrot)

By Carl O'Donnell

Stocks treated in this article : Eli Lilly and Company, Dermira, Inc.
Stocks mentioned in the article
ChangeLast1st jan.
DERMIRA, INC. 0.00% 18.74 Delayed Quote.23.61%
ELI LILLY AND COMPANY -0.48% 141.12 Delayed Quote.7.37%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on DERMIRA, INC.
02/11DERMIRA : Amended tender offer statement by Third Party
PU
02/10AMENDED STATEMENT OF OWNERSHIP : Solicitation
PU
02/10DERMIRA : Statement of Ownership
PU
01/30Eli Lilly profit beat helps ease investor concerns over growth
RE
01/30ELI LILLY AND : Lilly Adjusts 2020 Guidance on Pending Acquisition
DJ
01/16DERMIRA : Eli Lilly targets quarterly deals of $1 billion-$5 billion in 2020 - C..
RE
01/13ELI LILLY AND : Lilly Announces Agreement to Acquire Dermira
AQ
01/10WeissLaw LLP Investigates Dermira, Inc.
PR
01/10Monteverde & Associates PC Announces an Investigation of DERMIRA, INC. - DERM
PR
01/10Dermira, Eli Lilly Shares Touch 52-week Highs After Deal News
DJ
More news
Financials (USD)
Sales 2019 94,0 M
EBIT 2019 -217 M
Net income 2019 -216 M
Debt 2019 -
Yield 2019 -
P/E ratio 2019 -4,45x
P/E ratio 2020 -4,40x
Capi. / Sales2019 10,9x
Capi. / Sales2020 14,6x
Capitalization 1 025 M
Chart DERMIRA, INC.
Duration : Period :
Dermira, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DERMIRA, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 21,88  $
Last Close Price 18,74  $
Spread / Highest target 33,4%
Spread / Average Target 16,7%
Spread / Lowest Target 0,05%
EPS Revisions
Managers
NameTitle
Thomas G. Wiggans Chairman & Chief Executive Officer
Andrew L. Guggenhime CFO & Principal Accounting Officer
Eugene Andrew Bauer Director & Chief Medical Officer
Christopher Horan Chief Technical Operations Officer
Jake R. Nunn Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
DERMIRA, INC.23.61%1 025
GILEAD SCIENCES3.97%85 473
VERTEX PHARMACEUTICALS11.36%63 215
REGENERON PHARMACEUTICALS6.21%43 494
WUXI APPTEC CO., LTD.19.14%25 835
GENMAB10.23%15 420